Home
Transformative medicines through transformational understanding of disease.
We enable confidence in biology.
Our platform
Let biology drive medicine.
Our platform enables us to determine what biology to prosecute with unprecedented confidence. Based on these insights, we let the biology drive how we treat a disease — operating in an agnostic manner to modality.
Braid
Our pipeline
Medicines that matter.
We develop medicines to clinical value inflection points — either via de-novo discovery or in-licensed. Our pipeline spans bone, cardio-renal, dermatology and rheumatology.
Internal
- Osteoporosis / antibody and small molecule lead op phase
- Chronic kidney disease platform validation phase
Partnered
- Skin fibrosis end of platform validation phase
- Atopic diseases
- Osteoarthritis platform validation phase
- Project Morgan platform validation phase
Our Team
World-class drug developers, computational scientists and entrepreneurs.
With experience across biopharma and tech.
Our platform
Confidence in what biology to prosecute, using our proprietary data and AI platforms.
Read our news.
Read more-
Relation unveils MORGAN, the next-generation model of cellular biology
Global Newswire
Press release 30 Jul 2026
-
Relation promises 'transformationally different success rates' in expanded AI pact with GSK
Endpoints news
In the news 30 Jul 2026
-
Relation Announces Expanded Collaboration with GSK
Global newswire
Press release 30 Jul 2026
-
GSK pens $110M biological datasets pact with AI biotech Relation
Fierce Biotech
In the news 30 Jul 2026